Focus: Century Therapeutics is a public biotech company headquartered in Philadelphia specializing in induced pluripotent stem cell (iPSC) therapy platforms for cell therapy applications. The company is in early-stage clinical development with a heavily R&D-focused business model.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Century Therapeutics offers exposure to cutting-edge iPSC platform science and early clinical catalysts, but extreme cash burn, minimal hiring velocity, and product portfolio ambiguity present material career risk for job seekers seeking stability.
Legacy generic products in post-LOE status; minimal revenue contribution and strategic relevance to iPSC platform thesis.
Help build intelligence for Century Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Century Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading. - Hot Community Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading. - Hot Community Stocks Cổng thông tin điện tử tỉnh Tây Ninh
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March MarketBeat
Century Therapeutics (IPSC) seeks vote to add 150M shares, ratify EY - Stock Titan
Century Therapeutics (IPSC) seeks vote to add 150M shares, ratify EY Stock Titan
Century Therapeutics (IPSC) awards 88,000 stock options to new director - Stock Titan
Century Therapeutics (IPSC) awards 88,000 stock options to new director Stock Titan
Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 - Stock Titan
Century Therapeutics (IPSC) director Martin Patrick Murphy files initial Form 3 Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo